Close up of an abstract AI human face sideways. Technology background

Dermatology

Dermatology trials from first-in-human (FIH) through Phase 1b and proof-of-concept (PoC) studies, across a range of dermatologic indications and clinical assessments. Focused dermatology expertise and integrated CRO execution support efficient, well-coordinated study delivery from start-up through completion.

Discuss your dermatology trial
Board-Certified

Dermatologist on staff

0 +

Active dermatology sites

Indications and study types

Our site intelligence spans high-volume inflammatory conditions and smaller, procedure-intensive patient populations. For each protocol, DVCR evaluates indication-specific patient access against age, disease severity, prior therapy, washout requirements, procedural capabilities, competing studies and site start-up readiness.

Indications

Atopic dermatitis

Psoriasis

Alopecia

Acne

Hidradenitis suppurativa

Vitiligo

Study types

Early-phase and First-in-Human (FIH) Studies

Early-phase, first-in-human studies requiring a controlled, well-resourced clinical research environment

Proof-of-Concept and Dose-Ranging Studies
  • Outpatient proof-of-concept (PoC) studies
  • Dose-ranging studies
Pediatric and Adult Studies

Pediatric and adult protocols, with population access confirmed through feasibility assessments

Biopsy and Biomarker Studies
  • Biopsy-intensive studies
  • Biomarker-driven protocols requiring specialized sample collection and processing workflows
Dermatology Treatment Studies
  • Topical therapies
  • Oral therapies
  • Injectable therapies
  • Intravenous (IV) therapies

Dermatology assessments

Endpoint readiness

Establish investigator and assessor qualifications, training, and calibration for protocol-specific measures like EASI, SCORAD, IGA/vIGA, PASI, BSA, lesion counts and other disease-specific severity scales.

Standardized image capture

Define lesion selection, photography standards, metadata requirements, image transfer, privacy and central-review workflows before participant enrollment begins.  

Biopsy and biomarker operations

  • Prequalify procedure space, staff competency, biopsy & tape stripping capabilities, sample processing, PBMC or flow-cytometry requirements and shipping timelines.  
  • Across our dermatology network, sites have capabilities including punch biopsy, tape stripping, PBMC isolation and preservation and challenge testing to support complex early phase studies.

Participant-reported outcomes

Align itch, pain, sleep, treatment satisfaction and dermatology quality-of-life measures with visit burden, protocol requirements and ePRO workflows.

Recruitment design

Map patient phenotype, disease severity, age, prior therapies, washout burden, geography, and referral pathways and competing studies to realistic site-level enrollment assumptions.

Protocol-fit site selection

Translate each protocol into a site-level capability profile, with a clear rationale for why each site fits, what could limit performance and how those risks will be managed before selection.

Endpoint quality oversight

Monitor missing assessments, protocol deviations, query aging, data-cleaning trends and other signals that could affect endpoint quality throughout the study.

Dermatology infrastructure and partnerships

Dr Hull speaking with a peer

Clinical pharmacology unit

Our physician-led clinical pharmacology unit supports complex studies requiring inpatient stays, intensive PK sampling, continuous safety monitoring and complex multi-period designs, so studies with demanding monitoring or dosing requirements can be executed in a controlled environment. The unit accommodates both healthy volunteer and patient cohorts.

Multicenter trials

For multicenter patient trials, we draw on an established network of strategic site partners with documented experience enrolling healthy normal and patient populations. Site selection and ongoing oversight are managed by our Site Partnerships Team, with criteria aligned to investigator experience, enrollment track record and data quality standards, helping sponsors achieve consistent execution across participating sites. 

Through our Lead Site Model, we can serve as both the CRO and the first enrolling clinical research unit, providing firsthand operational insight that helps strengthen protocol compliance, improve feasibility and identify potential challenges before they impact study conduct. This approach supports faster site readiness, streamlined communication between sponsors and sites and delivers consistent execution across the study lifecycle.

Lab team at work in the research lab

Central lab

Our Central Laboratory supports multicenter studies with laboratory manual development, kit production, site supply logistics, and standardized specimen management. Centralized laboratory data and real-time access to results help improve data consistency across sites, supports safety oversight and streamlines study execution from startup through final reporting.

PK processing &
safety laboratory

Our CLIA-certified PK Processing & Safety Laboratory provides on-site safety testing, endpoint sample processing and real-time access to safety laboratory results. Integrated technology and barcode-enabled workflows support efficient study execution, data quality and timely study decisions. 

Dr vince clinical research laboratory employee

Pharmacy services

Study drug is prepared and stored on-site in our 2,500 sq. ft. cGMP-compliant pharmacy, which is DEA-registered to handle and store Schedule I-V controlled substances. The pharmacy is equipped to prepare investigational products across multiple routes of administration, including injectable formulations, nasal insufflation, powder-in-capsule, powder-in-solution and over-encapsulation. Integration within our Phase I unit enables rapid delivery of prepared doses under controlled conditions, reducing the number of handoffs, maintaining chain of custody and delivering on-time dosing. 

Technology and data visibility

Our fully integrated technology platform, including eSource, EDC, and CTMS, along with AI-driven tools help streamline data collection throughout the study. These secure, cloud-based systems provide real-time data visibility, validated audit trails, data integration and scalable access to reliable, high-quality data across the entire study lifecycle.

Our dermatology leadership

Beyond dermatology expertise, sponsors benefit from integrated CRO services that support study execution from startup through final reporting. Clinical operations, project management and medical monitoring provide coordinated oversight across sites, participants and protocol activities. Data management and biostatistics support the collection, review and analysis of high-quality data, while central laboratory services help standardize specimen management and laboratory processes across the study. 

Bradley Vince, DO

CEO & Chief Medical Officer

25 years of experience

Steven Hull, MD

Medical Director & Principal Investigator

25 years of experience

Korey Nevitt

Executive Director, Site Partnerships

25+ years of experience

Close up of an abstract AI human face sideways. Technology background

Featured study

Challenge

A sponsor required a Phase I program evaluating a novel investigational therapy across single ascending dose (SAD), multiple ascending dose (MAD) and moderate-to-severe atopic dermatitis patient cohorts. The program needed to generate safety, pharmacokinetic and pharmacodynamic data while supporting progression from healthy volunteers into the target patient population. Execution was further complicated by intensive biomarker sampling, skin biopsies, tape stripping, multiple laboratory workflows and the recruitment requirements of a defined atopic dermatitis population.

Approach

We supported the study across both healthy volunteer and moderate-to-severe atopic dermatitis cohorts, integrating clinical pharmacology, dermatology operations, recruitment and cross-functional study execution. The protocol included 4 skin punch biopsies and 6 tape strips per participant, standardized photography of atopic dermatitis lesions and exploratory assessment of 21 biomarker analytes across 4 specialty laboratories. We coordinated site readiness across five active sites, procedure execution, image capture, sample collection and processing, laboratory workflows, external recruitment support and cross-site operational oversight to maintain consistency across the program and generate high-quality data for development decisions.

Outcome

The study generated the required safety, PK and PD data. By executing both healthy volunteer and atopic dermatitis cohorts within a single integrated protocol, and coordinating the specialized procedures, biomarker workflows, laboratories and recruitment requirements that accompanied them, we delivered the data necessary to advance the asset through early clinical development.

Related resources

Considering DVCR for your dermatology trial?

Talk to a team with dermatology clinical development and operational expertise.

Whether you are planning a FIH study, a PoC program, or a multicenter patient trial, we can help assess your protocol, timeline, patient population, and operational requirements early. Our team brings together feasibility, protocol-fit site strategy, recruitment planning, and study-specific operational considerations to support efficient startup, enrollment and execution.

Request a Capabilities Meeting Download our CRO Services Info Sheet